Patient characteristics
| No. of patients | 206 |
| Prior to progression | |
| Primary histology | |
| Nodular sclerosis | 140 (68%) |
| Mixed cellularity | 46 (22%) |
| Lymphocyte depleted | 11 (5%) |
| Lymphocyte predominant | 5 (3%) |
| Not classified | 4 (2%) |
| Front-line chemotherapy | |
| COPP/ABVD | 111 (54%) |
| COPP/ABV/IMEP | 57 (28%) |
| BEACOPP (baseline) | 31 (15%) |
| BEACOPP (escalated) | 7 (3%) |
| Prior radiotherapy | 77 (37%) |
| Remission attained before progression | 148 (72%) |
| At progression | |
| Median age (range) | 34 (16-71) |
| Gender | |
| Male | 112 (54%) |
| Female | 94 (46%) |
| Stage | |
| I | 24 (11%) |
| II | 64 (31%) |
| III | 37 (18%) |
| IV | 81 (40%) |
| B symptoms | 97 (47%) |
| Karnofsky performance score < 90 | 48 (23%) |
| Time of progression | |
| During first-line treatment | 143 (70%) |
| During 90 d after first-line treatment | 63 (30%) |
| Sites of progression | |
| Previously involved sites only | 91 (44%) |
| New sites only | 15 (7%) |
| Both | 97 (47%) |
| Not known | 3 (2%) |
| After progression | |
| Salvage therapy | |
| Chemotherapy | 153 (74%) |
| Radiotherapy | 47 (23%) |
| No further salvage therapy | 6 (3%) |
| Sensitivity to conventional salvage chemotherapy | |
| Sensitive | 66 (43%) |
| Resistant | 87 (57%) |
| High-dose chemotherapy | |
| BEAM | 38 (54%) |
| CVB | 22 (31%) |
| Others | 10 (15%) |
| No. of patients | 206 |
| Prior to progression | |
| Primary histology | |
| Nodular sclerosis | 140 (68%) |
| Mixed cellularity | 46 (22%) |
| Lymphocyte depleted | 11 (5%) |
| Lymphocyte predominant | 5 (3%) |
| Not classified | 4 (2%) |
| Front-line chemotherapy | |
| COPP/ABVD | 111 (54%) |
| COPP/ABV/IMEP | 57 (28%) |
| BEACOPP (baseline) | 31 (15%) |
| BEACOPP (escalated) | 7 (3%) |
| Prior radiotherapy | 77 (37%) |
| Remission attained before progression | 148 (72%) |
| At progression | |
| Median age (range) | 34 (16-71) |
| Gender | |
| Male | 112 (54%) |
| Female | 94 (46%) |
| Stage | |
| I | 24 (11%) |
| II | 64 (31%) |
| III | 37 (18%) |
| IV | 81 (40%) |
| B symptoms | 97 (47%) |
| Karnofsky performance score < 90 | 48 (23%) |
| Time of progression | |
| During first-line treatment | 143 (70%) |
| During 90 d after first-line treatment | 63 (30%) |
| Sites of progression | |
| Previously involved sites only | 91 (44%) |
| New sites only | 15 (7%) |
| Both | 97 (47%) |
| Not known | 3 (2%) |
| After progression | |
| Salvage therapy | |
| Chemotherapy | 153 (74%) |
| Radiotherapy | 47 (23%) |
| No further salvage therapy | 6 (3%) |
| Sensitivity to conventional salvage chemotherapy | |
| Sensitive | 66 (43%) |
| Resistant | 87 (57%) |
| High-dose chemotherapy | |
| BEAM | 38 (54%) |
| CVB | 22 (31%) |
| Others | 10 (15%) |